IP Library Granted Patent US 7,906,150
Granted Patent B2
US 7,906,150 · App. 11/754,524 · Granted Mar 15, 2011

Preparation derived from shark cartilage for treatment of diseases related to excessive PHF or excessive intracellular calcium

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,906,150
App. No.
11/754,524
Granted
Mar 15, 2011
Kind
B2
Abstract

Shark cartilage extract has been shown to be an antagonist of parathyroid hypertensive factor (PHF). In view of this, shark cartilage extract can be used to treat conditions related to excessive PHF activity. Such diseases include hypertension and some other diseases related to intracellular calcium elevation. Methods for producing the shark cartilage extract and methods for administering the extract are disclosed.

Claims (10)

1. A method for treating a hypertensive condition related to excessive parathyroid hypertensive factor comprising: administering to a mammalian patient in need of such treatment, an effective amount of a shark cartilage extract having anti-parathyroid hypertensive factor activity, said amount effective to decrease blood pressure in said patient, and wherein the shark cartilage extract is produced by the following steps:

extracting cleaned, dried, ground shark cartilage with H 2 O at a temperature between 95-120° C. for 2-4 hours to provide a first suspension and cooling the first suspension to between 40-60° C.,

centrifuging the cooled first suspension at between 5200 to 5700 rpm to separate the first suspension into a first supernatant and a pellet,

holding the first supernatant in a cooling tank at 4-8° C.,

extracting said pellet with H2O at a temperature between 85-120° C. for 2-4 hours to provide a second suspension and cooling the second suspension to between 40-60° C.,

centrifuging the second suspension at between 5200-5700 rpm to separate the second suspension into a second supernatant and a pellet,

pooling the first supernatant with the second supernatant to provide pooled supernatants, and

spray drying the pooled supernatants to obtain the shark cartilage extract.

2. The method of claim 1 , wherein each extraction step is conducted at 95° C.

3. The method of claim 1 , wherein each extraction step is conducted for 2 hours.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2008
From: FX LIFE SCIENCES INTERNATIONAL GMBH
To: FX LIFE SCIENCES AG
Reel/Frame 022012/0925 →